Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Wakako Tajiri
CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
Related publications
Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer
Tumors of female reproductive system
Pretreatment Systemic Inflammation Response Index in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
Cancer Management and Research
Oncology
Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
Clinical Breast Cancer
Cancer Research
Oncology
PIK3CA H1047R Mutation Associated With a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated With Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
Cancer Research and Treatment
Cancer Research
Oncology
Neutrophil‐to‐lymphocyte Ratio as a Prognostic Factor in Advanced Stage Ovarian Carcinoma Treated With Neoadjuvant Chemotherapy
International Journal of Gynecology and Obstetrics
Medicine
Gynecology
Obstetrics
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity Before and After Neoadjuvant Chemotherapy
Cancers
Cancer Research
Oncology
The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
Bulletin of Siberian Medicine
Molecular Medicine
Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides
JAMA Dermatology
Dermatology
Medicine
Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer
OncoTargets and Therapy
Oncology
Pharmacology
